Xeris Biopharma Holdings, Inc. (XERS) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Xeris Biopharma Holdings, Inc. (XERS) closed at USD 9.77 on 2026-10-14, a change of +5.9 % over the past year, with a market capitalization of USD 1.84B.

Xeris Biopharma Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Xeris Biopharma Holdings, Inc. key figures

Previous close

USD 9.77 (2026-10-14)

1-year change

+5.9 %

Market cap

USD 1.84B

Enterprise value

USD 2B

P/E ratio (trailing)

-100.70

P/E ratio (forward)

27.22

EPS (trailing)

-0.10

EPS (forward)

0.37

PEG ratio

n/a

Price to book

-179.82

Revenue growth

28.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.45

Employees

435

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Xeris Biopharma Holdings, Inc. and compare it with other stocks.